Metaplastic Carcinoma of the Breast: Case Series of a Single Institute and Review of the Literature

Med Sci (Basel). 2023 May 19;11(2):35. doi: 10.3390/medsci11020035.

Abstract

Metaplastic carcinoma of the breast (MpBC) is a very rare and aggressive type of breast cancer. Data focusing on MpBC are limited. The aim of this study was to describe the clinicopathological features of MpBC and evaluate the prognosis of patients with MpBC. Eligible articles about MpBC were identified by searching CASES SERIES gov and the MEDLINE bibliographic database for the period of 1 January 2010 to 1 June 2021 with the keywords metaplastic breast cancer, mammary gland cancer, neoplasm, tumor, and metaplastic carcinoma. In this study, we also report 46 cases of MpBC stemming from our hospital. Survival rates, clinical behavior, and pathological characteristics were analyzed. Data from 205 patients were included for analysis. The mean age at diagnosis was 55 (14.7) years. The TNM stage at diagnosis was mostly stage II (58.5%) and most tumors were triple negative. The median overall survival was 66 (12-118) months, and the median disease-free survival was 56.8 (11-102) months. Multivariate Cox regression analysis revealed that surgical treatment was associated with decreased risk of death (hazard ratio 0.11, 95% confidence interval 0.02-0.54, p = 0.01) while advanced TNM stage was associated with increased risk of death (hazard ratio 1.5, 95% confidence interval 1.04-2.28, p = 0.03). Our results revealed that surgical treatment and TNM stage were the only independent risk factors related to patients' overall survival.

Keywords: breast cancer; metaplastic carcinoma; triple-negative breast cancer.

Publication types

  • Review

MeSH terms

  • Breast / pathology
  • Breast Neoplasms*
  • Carcinoma, Ductal, Breast* / pathology
  • Carcinoma, Ductal, Breast* / therapy
  • Disease-Free Survival
  • Female
  • Humans
  • Middle Aged
  • Prognosis

Grants and funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.